A Pivotal Trial to Determine the Efficacy and Safety of AP23573 (Ridaforolimus) when Administered as maintenance Therapy to Patients with Metastatic Soft-Tissue or Bone Sarcomas.

Trial Profile

A Pivotal Trial to Determine the Efficacy and Safety of AP23573 (Ridaforolimus) when Administered as maintenance Therapy to Patients with Metastatic Soft-Tissue or Bone Sarcomas.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Ridaforolimus (Primary)
  • Indications Osteosarcoma; Soft tissue sarcoma
  • Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms SUCCEED
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 28 May 2013 Results published in the Journal of Clinical Oncology.
    • 05 Jul 2012 EudraCT reports actual initiation date 03 Jun 2008.
    • 21 Apr 2012 Planned number of patients changed from 650 to 705 as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top